ImmunityBio (NASDAQ:IBRX) Director Christobel Selecky Sells 95,722 Shares

ImmunityBio, Inc. (NASDAQ:IBRX) Director Christobel Selecky sold 95,722 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $9.01, for a total value of $862,455.22. Following the sale, the director owned 32,173 shares of the company’s stock, valued at approximately $289,878.73. The trade was a 74.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christobel Selecky also recently made the following trade(s):

• On Tuesday, June 30th, Christobel Selecky sold 1,000 shares of ImmunityBio stock. The stock was sold at an average price of $9.00, for a total value of $9,000.00.

ImmunityBio Trading Up 5.0%

Shares of ImmunityBio stock opened at $9.20 on Thursday. The business’s fifty day moving average price is $7.65 and its 200 day moving average price is $6.67. ImmunityBio, Inc. has a twelve month low of $1.95 and a twelve month high of $12.43. The stock has a market capitalization of $9.64 billion, a P/E ratio of -10.82 and a beta of 0.01.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The business had revenue of $44.21 million during the quarter, compared to the consensus estimate of $43.07 million. As a group, sell-side analysts predict that ImmunityBio, Inc. will post -0.31 EPS for the current year.

Analyst Ratings Changes

IBRX has been the subject of several research reports. BTIG Research reiterated a “buy” rating and set a $12.00 price objective on shares of ImmunityBio in a research note on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of ImmunityBio in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a report on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.20.

Institutional Trading of ImmunityBio

A number of hedge funds and other institutional investors have recently modified their holdings of IBRX. Vestor Capital LLC acquired a new position in shares of ImmunityBio in the first quarter worth about $88,000. Arete Wealth Advisors LLC purchased a new stake in ImmunityBio during the 1st quarter worth approximately $4,500,000. Norris Financial Group LLC purchased a new stake in ImmunityBio during the 1st quarter worth approximately $108,000. Western Wealth Management LLC acquired a new position in shares of ImmunityBio in the 1st quarter valued at approximately $44,000. Finally, Bank of America Corp DE raised its position in shares of ImmunityBio by 2.7% in the 1st quarter. Bank of America Corp DE now owns 2,447,843 shares of the company’s stock valued at $18,775,000 after purchasing an additional 65,340 shares in the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.